Check it: A New Approach to Controlling Chlamydia Transmission in Young

Status Completed

Clinical Trial Summary

This study, named "Check it," is a bundled program for African American (AA) men ages 15-24 that includes community testing for chlamydia and gonorrhea, expedited treatment for subjects who test positive and their female sexual contacts, and rescreening for these two sexually transmitted infections.

Clinical Trial Description

Participants (N=4854) will be recruited through community partners, at events and using social marketing campaigns including advertisements, referrals from other participants, social media, and a web based educational website (Web-Ed). After establishing eligibility, written informed consent will be obtained. Subjects will complete a survey and provide a urine specimen for chlamydia (Ct) and gonorrhea (GC) testing and will provide their preferred contact information in order to be contacted about their test results. The testing laboratory will report positive results per LA hygiene code LAC 51:II.105: http://ldh.la.gov/assets/oph/Center-PHCH/Center-CH/infectious-epi/Surveillance/sanitarycode.p df. Tulane study staff will contact participants to inform them of their results. If the participant tests positive for Ct and/or GC, the subject will be offered expedited treatment for the subject and the subject's recent sex partners. The subject may choose to pick up medication at a local pharmacy or medication can be mailed to the subject. Staff will also ask the participant to contact his partner(s) and provide them with the Check It staff's contact information so that staff can let the partner know that they have been exposed to an infection and offer the subject's sexual partner expedited treatment options if the participant did not already provide the subject's sexual partners with that information. No information provided by the participant will be shared with his partners. The study will cover the cost of the medications for subjects who test positive for either or both organisms and their sexual partners. Three months after treatment, male subjects who were positive will be asked to be re-screened and if positive, staff will conduct similar expedited treatment and partner services. Any subject who provides consent for annual testing reminders will be reminded using their preferred method of contact. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03098329
Study type	Interventional
Source	Tulane University
Contact
Status	Completed
Phase	N/A
Start date	May 22, 2017
Completion date	May 28, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01439503` - Safer Sex Program for Young African-American Men	Phase 2
Completed	`NCT00381992` - Risk Assessment of Long-Haul Truck Drivers	N/A
Completed	`NCT03294395` - New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea	Phase 3
Not yet recruiting	`NCT06428643` - A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities	N/A
Completed	`NCT03896776` - A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0)	N/A
Completed	`NCT03718806` - Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin	Phase 1
Completed	`NCT04010539` - A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea	Phase 3
Completed	`NCT00262106` - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection	Phase 3
Completed	`NCT00187902` - Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM	N/A
Completed	`NCT00207506` - Lay Health Advisors for Sexually Transmitted Disease Prevention	Phase 1/Phase 2
Completed	`NCT04553068` - Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection	Phase 3
Active, not recruiting	`NCT03959527` - Zoliflodacin in Uncomplicated Gonorrhoea	Phase 3
Active, not recruiting	`NCT03980223` - Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men	Phase 4
Completed	`NCT01465607` - Implementation of an Efficacious Intervention for High Risk Women in Mexico	N/A
Terminated	`NCT00120770` - Cellulose Sulfate (CS) Gel and HIV in Nigeria	Phase 3
Completed	`NCT02391233` - Multimedia WORTH With Black Drug-Involved Women on Probation	N/A
Recruiting	`NCT05766904` - Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections	Phase 3
Completed	`NCT04297436` - Gonococcal Vaccine Study in Key Populations in Kenya	N/A
Completed	`NCT02122094` - Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities	N/A
Completed	`NCT01836445` - Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Check it: A New Approach to Controlling Chlamydia Transmission in Young People

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms